View Item 

Show simple item record

Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de‐implementation
dc.contributor.authorSkolarus, Ted A.
dc.contributor.authorCaram, Megan EV
dc.contributor.authorChapman, Christina H.
dc.contributor.authorSmith, David C.
dc.contributor.authorHollenbeck, Brent K.
dc.contributor.authorHawley, Sarah
dc.contributor.authorTsodikov, Alexander
dc.contributor.authorSales, Anne
dc.contributor.authorWittmann, Daniela
dc.contributor.authorZaslavsky, Alexander
dc.date.accessioned2018-12-06T17:36:58Z
dc.date.available2019-12-02T14:55:10Zen
dc.date.issued2018-10-15
dc.identifier.citationSkolarus, Ted A.; Caram, Megan EV; Chapman, Christina H.; Smith, David C.; Hollenbeck, Brent K.; Hawley, Sarah; Tsodikov, Alexander; Sales, Anne; Wittmann, Daniela; Zaslavsky, Alexander (2018). "Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de‐implementation." Cancer (20): 3971-3974.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/146605
dc.publisherWiley Periodicals, Inc.
dc.publisherNCCN
dc.titleCastration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de‐implementation
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146605/1/cncr31665_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146605/2/cncr31665.pdf
dc.identifier.doi10.1002/cncr.31665
dc.identifier.sourceCancer
dc.identifier.citedreferencePotosky AL, Haque R, Cassidy‐Bushrow AE, et al. Effectiveness of primary androgen‐deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014; 32: 1324 ‐ 1330.
dc.identifier.citedreferenceSammon JD, Abdollah F, Reznor G, et al. Patterns of declining use and the adverse effect of primary androgen deprivation on all‐cause mortality in elderly men with prostate cancer. Eur Urol. 2015; 68: 32 ‐ 39.
dc.identifier.citedreferenceSkolarus TA, Wolf AM, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014; 64: 225 ‐ 249.
dc.identifier.citedreferenceHuggins C, Hodges, CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22: 232 ‐ 240.
dc.identifier.citedreferenceJang TL, Bekelman JE, Liu Y, et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med. 2010; 170: 440 ‐ 450.
dc.identifier.citedreferenceWidmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG‐7/SFUO‐3): an open randomised phase III trial. Lancet. 2009; 373: 301 ‐ 308.
dc.identifier.citedreferenceYang DD, Mahal BA, Muralidhar V, et al. Receipt of definitive therapy in elderly patients with unfavorable‐risk prostate cancer. Cancer. 2017; 123: 4832 ‐ 4840.
dc.identifier.citedreferenceDeyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. J Clin Epidemiol. 1992; 45: 613 ‐ 619.
dc.identifier.citedreferenceNational Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Version 2.2017. Fort Washington, PA: NCCN; 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
dc.identifier.citedreferenceStuder UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006; 24: 1868 ‐ 1876.
dc.identifier.citedreferenceStuder UE, Whelan P, Wimpissinger F, et al. Differences in time to disease progression do not predict for cancer‐specific survival in patients receiving immediate or deferred androgen‐deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow‐up. Eur Urol. 2014; 66: 829 ‐ 838.
dc.identifier.citedreferenceStuder UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0–4 N0–2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008; 53: 941 ‐ 949.
dc.identifier.citedreferenceLu‐Yao GL, Albertsen PC, Moore DF, et al. Fifteen‐year survival outcomes following primary androgen‐deprivation therapy for localized prostate cancer. JAMA Intern Med. 2014; 174: 1460 ‐ 1467.
dc.identifier.citedreferenceCane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research [serial online]. Implement Sci. 2012; 7: 37.
dc.identifier.citedreferenceSchweizer MT, Antonarakis ES, Wang H et al. Effect of bipolar androgen therapy for asymptomatic men with castration‐resistant prostate cancer: results from a pilot clinical study [serial online]. Sci Transl Med. 2015; 7: 269 ‐ 262.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr31665_am.pdf
Size:
238.1KB
Format:
PDF
View/Open
Name:
cncr31665.pdf
Size:
93.84KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.